Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Harmony Biosciences Holdings (HRMY)

Harmony Biosciences reports ~$868 million 2025 WAKIX revenue, guides 2026 to $1.0-1.04 billion

Positive Impact 3 of 5 earnings Written later

Harmony Biosciences said preliminary unaudited WAKIX net product revenue was about $868 million for 2025, up from $714.7 million in 2024, and about $243 million for the fourth quarter, up from $201.3 million a year earlier. It also issued 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and said it is phasing out its ZYN002 Fragile X program. The figures are unaudited and may change after year-end closing and auditor review.

Key points

  • Preliminary 2025 WAKIX net product revenue of about $868 million, versus $714.7 million in 2024 (about 21% growth)
  • Q4 2025 preliminary net product revenue of about $243 million, versus $201.3 million in Q4 2024
  • 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion for the year ending December 31, 2026
  • ZYN002 Fragile X program being phased out after review of RECONNECT study data; 22q deletion indication no longer pursued

The filing

CompanyHarmony Biosciences Holdings (HRMY)
Form8-K, current report
Filed with the SECJan 12, 2026, 8:20 AM ET
Accession number0001104659-26-002731

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.